---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-036769"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2022-11-04T23:59:59+00:00"
generated_at: "2026-06-22T07:03:33.748910+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Aptevo extends shareholder rights plan expiration to November 4, 2023

## Summary
- Amendment No. 2 to Rights Agreement extends Final Expiration Date to Nov 4, 2023.
- Rights Agreement originally dated Nov 8, 2020, amended Nov 5, 2021, and now Nov 4, 2022.
- Rights pertain to contingent purchase of one one-thousandth of Series A Junior Participating Preferred Stock.
- Broadridge Corporate Issuer Solutions remains Rights Agent.
- No changes to other terms or exercise price of rights.

## SEC filing metadata
- accession: 0001564590-22-036769
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2022-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 1.01, 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000156459022036769/0001564590-22-036769-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000156459022036769/apvo-8k_20221104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-036769
- JSON: https://secwatch.observer/filing/0001564590-22-036769.json
- Plain text: https://secwatch.observer/filing/0001564590-22-036769.txt

## Key facts
- Material Agreements
  Aptevo Therapeutics Inc. amended "Rights Agreement" with Broadridge Corporate Issuer Solutions, Inc. valued at 1011 (effective 2022-11-04).
  - Action: amendment
  - Counterparty: Broadridge Corporate Issuer Solutions, Inc.
  - Value: 1011
  - Effective: 2022-11-04
  source text: On November 4, 2022, Aptevo Therapeutics Inc. (the “Company”) entered into Amendment No. 2 (the “Amendment”) to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent, as amended on November 5, 2021 (the “Rights Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671584/000156459022036769/0001564590-22-036769-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.